Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Josh Northey"'
Autor:
Peter Hoskin, Marina Lee, Denise Dunkley, Mary Danh, Robin Wickens, Geoff Saunders, Josh Northey, Simon Crabb, Vicky McFarlane, Azmat Sadozye, Rachel Cooper, Tony Mathew, Kate Haslett, Kim Reeves, Rachel Reed, Kamilla Bigos, Kaye J. Williams, Emily Rowling, Ananya Choudhury, Sonia Dancer, Deb Smith, Gareth Griffiths
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-10 (2024)
Abstract Background Cervical cancer is the fourth most common cancer in women, with an estimated 342,000 deaths worldwide in 2020. Current standard of care in the UK for locally advanced cervical cancer is concurrent chemoradiotherapy with weekly cis
Externí odkaz:
https://doaj.org/article/f7ea589d3ca34f57b9365cb0b9d214d5
Autor:
I’ah Donovan-Banfield, Rebekah Penrice-Randal, Hannah Goldswain, Aleksandra M. Rzeszutek, Jack Pilgrim, Katie Bullock, Geoffrey Saunders, Josh Northey, Xiaofeng Dong, Yan Ryan, Helen Reynolds, Michelle Tetlow, Lauren E. Walker, Richard FitzGerald, Colin Hale, Rebecca Lyon, Christie Woods, Shazaad Ahmad, Dennis Hadjiyiannakis, Jimstan Periselneris, Emma Knox, Calley Middleton, Lara Lavelle-Langham, Victoria Shaw, William Greenhalf, Thomas Edwards, David G. Lalloo, Christopher J. Edwards, Alistair C. Darby, Miles W. Carroll, Gareth Griffiths, Saye H. Khoo, Julian A. Hiscox, Thomas Fletcher
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-9 (2022)
Molnupiravir is an antiviral that forces lethal error catastrophe in SARS-CoV-2 RNAs. Here, the authors confirm the mechanism of action of molnupiravir in humans using samples obtained from the UK’s AGILE phase IIa clinical trial investigating the
Externí odkaz:
https://doaj.org/article/ce55d33708154cc1b4167b313d922661
Autor:
Saye H Khoo, Richard FitzGerald, Geoffrey Saunders, Calley Middleton, Shazaad Ahmad, Christopher J Edwards, Dennis Hadjiyiannakis, Lauren Walker, Rebecca Lyon, Victoria Shaw, Pavel Mozgunov, Jimstan Periselneris, Christie Woods, Katie Bullock, Colin Hale, Helen Reynolds, Nichola Downs, Sean Ewings, Amanda Buadi, David Cameron, Thomas Edwards, Emma Knox, I'ah Donovan-Banfield, William Greenhalf, Justin Chiong, Lara Lavelle-Langham, Michael Jacobs, Josh Northey, Wendy Painter, Wayne Holman, David G Lalloo, Michelle Tetlow, Julian A Hiscox, Thomas Jaki, Thomas Fletcher, Gareth Griffiths, Nicholas Paton, Fred Hayden, Janet Darbyshire, Amy Lucas, Ulrika Lorch, Andrew Freedman, Richard Knight, Stevan Julious, Rachel Byrne, Ana Cubas Atienzar, Jayne Jones, Chris Williams, Anna Song, Jan Dixon, Anja Alexandersson, Parys Hatchard, Emma Tilt, Andrew Titman, Ale Doce Carracedo, Vatsi Chandran Gorner, Andrea Davies, Louis Woodhouse, Nicola Carlucci, Emmanuel Okenyi, Marcin Bula, Kate Dodd, Jennifer Gibney, Lesley Dry, Zalina Rashid Gardner, Amin Sammour, Christine Cole, Tim Rowland, Maria Tsakiroglu, Vincent Yip, Rostam Osanlou, Anna Stewart, Ben Parker, Tolga Turgut, Afshan Ahmed, Kay Starkey, Sujamole Subin, Jennifer Stockdale, Lisa Herring, Jonathon Baker, Abigail Oliver, Mihaela Pacurar, Dan Owens, Alistair Munro, Gavin Babbage, Saul Faust, Matthew Harvey, Danny Pratt, Deepak Nagra, Aashish Vyas
Background: the antiviral drug molnupiravir was licensed for treating at-risk patients with COVID-19 on the basis of data from unvaccinated adults. We aimed to evaluate the safety and virological efficacy of molnupiravir in vaccinated and unvaccinate
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::06e70d9e57376aff40b8667277b718e2
https://eprints.soton.ac.uk/472664/
https://eprints.soton.ac.uk/472664/
Autor:
Simon J. Crabb, Gareth Griffiths, Denise Dunkley, Nichola Downs, Mary Ellis, Mike Radford, Michelle Light, Josh Northey, Amy Whitehead, Sam Wilding, Alison J. Birtle, Vincent Khoo, Robert J. Jones
The PI3K/AKT/PTEN pathway is frequently deregulated in metastatic castration-resistant prostate cancer (mCRPC). ProCAID was a phase 2 trial assessing addition of the AKT1/2/3 inhibitor capivasertib to docetaxel for patients with mCRPC. We previously
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3e40ee055834e5a7de1b5b5b7f80a9c1
https://eprints.gla.ac.uk/271608/1/271608.pdf
https://eprints.gla.ac.uk/271608/1/271608.pdf
Autor:
Gareth Griffiths, Satinder Jagdev, Christine Stephens, Amit Bahl, Simon J. Crabb, Charlotte Westbury, Michelle Light, Satish Kumar, Ellice Marwood, Denise Dunkley, Carolina Salinas-Souza, Tony Elliott, Angus Robinson, Santhanam Sundar, Emily C. Shaw, Josh Northey, Amy Whitehead, Karen Martin, Alison Birtle, Robert Jones, Nichola Downs, Sam Wilding, Claire Rooney, Vincent Khoo
Publikováno v:
Journal of Clinical Oncology
PURPOSE Capivasertib is a pan-AKT inhibitor. Preclinical data indicate activity in metastatic castration-resistant prostate cancer (mCRPC) and synergism with docetaxel. PATIENTS AND METHODS ProCAID was a placebo controlled randomized phase II trial i
Autor:
Simon J. Crabb, Gareth Owen Griffiths, Denise Dunkley, Nichola Downs, Mary Ellis, Mike Radford, Michelle Light, Josh Northey, Amy Whitehead, Sam Wilding, Claire Rooney, Carolina Salinas-Souza, Alison Jane Birtle, Vincent Khoo, Robert J. Jones
Publikováno v:
Journal of Clinical Oncology. 40:108-108
108 Background: The AKT pathway is frequently deregulated in mCRPC. ProCAID tested addition of capivasertib, a potent selective inhibitor of all three AKT isoforms (AKT1/2/3) to docetaxel chemotherapy vs. placebo plus docetaxel for mCRPC. The primary
Autor:
Amy Whitehead, Satinder Jagdev, Alison Birtle, Tony Elliott, Vincent Khoo, Gareth Griffiths, Santhanam Sundar, Josh Northey, Karen Martin, Michelle Light, Ellice Marwood, Emily C. Shaw, Simon J. Crabb, Angus Robinson, Robert Jones, Amit Bahl, Satish Kumar, Nichola Downs, Denise Dunkley, Charlotte Westbury
Publikováno v:
Journal of Clinical Oncology. 38:5520-5520
5520 Background: DP extends survival in mCRPC, but clinical benefit is modest. PI3K/AKT/PTEN pathway activation is common in mCRPC contributing to disease progression and DP resistance. C is a pan-AKT inhibitor. Pre-clinical data indicate activity in